ERBB2 and colorectal carcinoma: Molecular characterization is also key to direct therapy in breast and colorectal cancer (CRC), for which anti-ERBB2 and anti-EGFR agents, respectively, represent the backbone of therapeutic regimens in certain subtypes defined by distinct genetic features such as ERBB2 amplification or the absence of a KRAS mutation [5,6].